We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · April 20, 2021

Pembrolizumab+Chemotherapy vs Atezolizumab+Chemotherapy±Bevacizumab for First-Line Treatment of Non-Squamous NSCLC

Lung Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

Lung Cancer
Pembrolizumab+Chemotherapy Versus Atezolizumab+Chemotherapy+/-Bevacizumab for the First-Line Treatment of Non-Squamous NSCLC: A Matching-Adjusted Indirect Comparison
Lung Cancer 2021 Mar 30;[EPub Ahead of Print], B Halmos, T Burke, C Kalyvas, K Vandormael, A Frederickson, B Piperdi

Further Reading